The introduction of immunotherapy (IMTx) has led to a paradigm shift in the treatment of patients with metastatic cancer. Particular interest has been directed towards combining IMTx with stereotactic radiosurgery (SRS) to improve treatment response. Lately, studies have indicated that the timing of IMTx with SRS may be crucial for the patient outcome, suggesting that there is a window of opportunity to induce an optimal synergy between irradiation and immune agents. To this end, this work investigates whether the timing of IMTx with SRS affects the outcome of patients with brain metastases.
This abstract and the presentation materials are available to members only; a login is required.